Drug Discovery
AI-Driven Drug Discovery & Patient Stratification
Transformative Multi-Omics Platform for Drug Repurposing
Traditional “one disease–one target” models oversimplify the complex, multifactorial nature of disease. We shift this focus entirely by analyzing whole-disease molecular signatures to identify more effective therapeutic interventions.
Our proprietary AI-driven pipeline integrates high-resolution multi-omics data from patient tissues, cells, and clinical repositories to map disease progression. By using advanced computational pattern-matching algorithms, we identify and rank already approved FDA/EMA drugs predicted to reverse the entire disease signature back to a healthy state.
The Mosaiques Advantage: Proprietary Data
The unparalleled accuracy of our pipeline rests on Mosaiques' proprietary proteome database-the world's largest repository of its kind, containing over 100,000+ individual clinical datasets. Each dataset is fully quality-controlled and intricately linked with clinical, demographic, and long-term patient follow-up data.
Figure 1: Mosaiques’ Innovative Drug Identification and Stratification Pipeline
Our Five- Step Pipeline
We translate complex molecular biology into actionable therapeutic candidates through a transparent, five-step process:
- Step 1: Disease Fingerprinting: We analyze multi-omics data (proteomics/transcriptomics) from patient samples at various disease stages to map the unique "molecular fingerprint" of disease progression.
- Step 2: Multi-Omics Data Integration: We merge our proprietary database with public repositories, computing a composite score to bypass analytical biases and isolate only the most highly validated disease drivers.
- Step 3: In Silico Drug Reversion: Using the CMap pattern-matching algorithm, we screen thousands of approved compounds to identify those with the highest mathematical potential to completely reverse the disease signature back to a healthy state.
- Step 4: Smart Filtering & Prioritization: Candidates are screened against databases (e.g. DrugBank, SIDER) to prioritize FDA/EMA-approved drugs with optimal safety profiles, active patents, and novelty for the target indication.
- Step 5: Rapid Preclinical Validation: Top-tier candidates undergo in vitro and in vivo testing to confirm efficacy. Since these drugs have established safety profiles, validated candidates bypass Phase I and move directly to Phase II trials.
Value Proposition for Pharma Partners
We de-risk pharma pipelines by focusing on high-probability, evidence-based success.
- Bypass Phase I Clinical Trials: Focus on FDA/EMA-approved drugs with established safety profiles allows candidates to transition directly into Phase II trials.
- Accelerated Timelines: Shorten traditional drug discovery and preclinical research phases by up to 5 years.
- Drastic Cost Reduction: Save approximately €1 billion in R&D costs by eliminating blind, high-throughput screening of massive, uncharacterized compound libraries.
- Protected Intellectual Property: Our innovative workflow is fully protected by international and European patent applications (PCT/EP2024/055936; EP 23160357.2).
Figure 2: Our Drug Identification Platform vs. Traditional R&D
Proof-of-Concept, Active Pipeline & Translational Initiatives
Our platform is supported by robust preclinical validation and a highly successful oncology test-case. We provide a clear, data-driven roadmap from computational prediction to in vivo efficacy and clinical translation.
The successful development and validation of our platform was achieved through two major, competitively awarded European research grants:
- ReDrugBC Project: (Grant Agreement ID: 898260; H2020-MSCA-IF-2019) – Funded under the European Union’s Horizon 2020 framework.
- ReDiRECt Project: (Project E! 113726; Eurostars) – Supported by the Eurostars program.
Through these projects Mosaiques developed a drug identification pipeline using bladder cancer as a proof-of-concept. Rather than relying on raw tissue data-which can often be distorted by non-cellular material-our platform integrates tissue and cell-line multi-omics (proteotranscriptomics). This allows us to filter out noise and focus exclusively on highly credible therapeutic targets within tumor cells.
Our research and translational initiatives are powered by a multidisciplinary network of academic and clinical partners across Europe, including centers in Hannover, Düsseldorf, Athens, Innsbruck, and Córdoba. We have successfully expanded our stratified pipeline across multiple oncological indications:
- Bladder Cancer (Proof-of-Concept): Our pipeline identified compounds capable of reversing bladder cancer aggressiveness. Three compounds—exemestane, amiodarone, and fluvoxamine-demonstrated outstanding in vivo efficacy and are progressing toward clinical evaluation. Additionally, an EIC Accelerator application for the investigation of exemestane in a Phase I/II clinical trial has successfully passed the first phase.
- Cephaeline Development: Supported by the
Cephamed project (KMUi-Biomedizin-6, Funding: 03LWB0009A), Cephaeline has entered robust preclinical evaluation in bladder cancer toward clinical development.
- Prostate Cancer: Leveraging the
PROMOTE EU-funded MSCA Doctoral Network (Grant 101169245), we are expanding our platform to prostate cancer.
- Breast Cancer & Melanoma: Advanced computational modeling is ongoing to map stage-specific signatures for targeted repurposing is ongoing.
Guiding Intervention via Predictive Biomarkers
We don’t just find drugs; we find the exact patients who will respond to them. By utilizing predictive biomarkers to guide targeted intervention, we molecularly stratify patient cohorts. This stratified medicine approach ensures that clinical trials are populated only by individuals whose specific multi-omics signatures match the drug's mechanism of action, dramatically maximizing clinical trial success and de-risking pharma pipelines.
Partner With Us
We are actively seeking pharmaceutical and clinical partners to leverage our multi-omics database, validate novel target signatures, and co-develop stratified clinical trials.